|
시장보고서
상품코드
2049453
알파 1 항트립신 결핍증 치료 시장 보고서 : 치료법별, 투여 경로별, 최종사용자별, 지역별(2026-2034년)Alpha 1 Antitrypsin Deficiency Treatment Market Report by Treatment Type, Route of Administration, End User, and Region 2026-2034 |
||||||
세계의 알파 1 항트립신 결핍증 치료 시장 규모는 2025년에 23억 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 44억 달러에 달하며, 2026-2034년에 CAGR 7.14%로 성장할 것으로 예측하고 있습니다.
알파1 항트립신(AAT) 결핍증은 체내에서 충분한 AAT 단백질이 생성되지 않는 유전성 질환을 말합니다. AAT 단백질은 체내의 다른 단백질에 의한 부작용으로부터 폐와 간을 보호하는 데 필수적입니다. AAT 결핍이 심한 환자는 간경화, 만성폐쇄성폐질환(COPD), 폐기종 등이 발생할 수 있습니다. 이 질환은 유전자 검사나 혈액 검사를 통해 진단합니다. 치료법으로는 강화요법, 폐 재활치료, 산소요법 등이 있으며, 기관지확장제나 코르티코스테로이드와 같은 약물을 정맥주사나 흡입을 통해 사용하기도 합니다.
호흡기 질환의 유병률 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 또한 강화 요법의 보급이 시장 성장에 탄력을 받고 있습니다. 이 치료법은 건강한 기증자의 혈장에서 AAT 단백질을 추출하여 환자의 기도내 AAT 농도를 높이는 치료법입니다. 이에 따라 이 치료법은 폐기종의 진행을 늦추고, 악화 빈도를 최소화하며, 회복 속도를 향상시켜 환자와 의료진 모두에게 점점 더 많은 지지를 받고 있습니다. 또한 진단법의 다양한 기술적 진보와 AAT의 제조 및 정제를 위한 혁신적인 공정의 개발도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 이들은 품질이 향상되어 바이러스나 박테리아 등의 오염물질이 포함되어 있지 않습니다. 또한 광범위한 연구개발(R&D) 활동과 의료 인프라 개선 등 다른 요인들도 시장을 더욱 견인할 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 알파 1 항트립신 결핍증 치료 시장
제6장 시장 내역 : 치료법별
제7장 시장 내역 : 투여 경로별
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSAThe global alpha 1 antitrypsin deficiency treatment market size reached USD 2.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 4.4 Billion by 2034, exhibiting a growth rate (CAGR) of 7.14% during 2026-2034.
Alpha-1 antitrypsin (AAT) deficiency refers to a genetic disorder due to which the body does not produce sufficient AAT protein. AAT protein is essential for protecting the lungs and liver from the adverse effects of other proteins in the body. Patients with severe AAT deficiency may develop liver cirrhosis, chronic obstructive pulmonary diseases (COPD) and emphysema diseases. It can be diagnosed through a genetic or a blood test. Some of the treatment methods include augmentation therapy, pulmonary rehabilitation and oxygen therapy that use medicines, such as bronchodilators and corticosteroids, which can be injected intravenously or inhaled.
The increasing prevalence of respiratory disorders is one of the key factors driving the growth of the market. Furthermore, widespread adoption of augmentation therapy is providing a thrust to the market growth. This therapy involves extracting AAT protein from a healthy donor's blood plasma for increasing AAT levels in the respiratory tract of patients. In line with this, this treatment also delays the progression of emphysema, minimizes the frequency of exacerbations and improves recovery speed, which, in turn, is contributing to its increasing preference among both the patients and healthcare providers. Additionally, various technological advancements in the diagnostic methods and the development of innovative processes for the production and purification of AAT are acting as other growth-inducing factors. They have improved quality and are free from contaminants, such as viruses and bacteria. Other factors, including extensive research and development (R&D) activities, along with improvements in medical infrastructure, are anticipated to drive the market further.
KEY MARKET SEGMENTATION:
Breakup by Treatment Type :
- Augmentation Therapy
- Bronchodilators
- Corticosteroids
- Oxygen Therapy
- Others
Breakup by Route of Administration:
- Parenteral
- Inhalation
- Oral
Breakup by End User:
- Hospitals
- Specialty Clinics
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined with some of the key players being AstraZeneca PLC, C.H. Boehringer Sohn AG & Ko. KG, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments S.A., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report
1. How big is the alpha 1 antitrypsin deficiency treatment market?
2. What is the future outlook of alpha 1 antitrypsin deficiency treatment market?
3. What are the key factors driving the alpha 1 antitrypsin deficiency treatment market?
4. Which region accounts for the largest alpha 1 antitrypsin deficiency treatment market share?
5. Which are the leading companies in the global alpha 1 antitrypsin deficiency treatment market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Alpha 1 Antitrypsin Deficiency Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Treatment Type
- 6.1 Augmentation Therapy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Bronchodilators
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Corticosteroids
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Oxygen Therapy
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Parenteral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Inhalation
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Oral
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Specialty Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AstraZeneca PLC
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 C.H. Boehringer Sohn AG & Ko. KG
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 CSL Limited
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 GlaxoSmithKline Plc
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Grifols S.A.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Kamada Ltd.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 LFB Biomedicaments S.A.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Pfizer Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Takeda Pharmaceutical Company Limited
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.10 Teva Pharmaceutical Industries Ltd.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.1 AstraZeneca PLC
